Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

Cited by (1,000)

Items 801–900 of 1,000

1. Case Report: Prolonged clinical benefit with sequential trastuzumab-containing treatments in a patient with advanced extramammary Paget disease of the groin
   Emma Zattarin, Federico Nichetti, Francesca Ligorio, Laura Mazzeo, Riccardo Lobefaro, Giovanni Fucà, Giorgia Peverelli, Andrea Vingiani, Giulia Bianchi, Giuseppe Capri et al. · 2022 · Frontiers in Oncology
2. The emergence of AntibodyPlus: the future trend of antibody-based therapeutics
   Yong Zhu, Shawn Shouye Wang, Zhaohui Sunny Zhou, Mitchell Ho · 2022 · Antibody Therapeutics
3. Prognostic significance of HER2 status evaluation using immunohistochemistry in patients with urothelial carcinoma of the bladder: A retrospective single‑center experience
   Xuesong Bai, Weiyang He, Hubin Yin, Xinyuan Li, Xiang Zhou, Zongjie Wei, Haitao Yu, Xin Gou · 2022 · Experimental and Therapeutic Medicine
4. Advances in antibody-drug conjugates for gynecologic malignancies
   Joan Tymon‐Rosario, Megan Gorman, Debra L. Richardson, Christina Renay Washington, Alessandro Davide Santin · 2022 · Current Opinion in Obstetrics & Gynecology
5. Clinical Significance of ABCG2/BCRP Quantified by Fluorescent Nanoparticles in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
   Hiroshi Tada, Kohsuke Gonda, Narufumi Kitamura, Takanori Ishida · 2023 · Cancers
6. Biparatopic anti-HER2 drug radioconjugates as breast cancer theranostics
   Jessica Pougoue Ketchemen, Hanan Babeker, Anjong Florence Tikum, Anand Krishnan Nambisan, Fabrice Ngoh Njotu, Emmanuel Nwangele, Humphrey Fonge · 2023 · British Journal of Cancer
7. Immuno-PET Detects Antibody–Drug Potency on Coadministration with Statins
   Emma L. Brown, Shayla Shmuel, Komal Mandleywala, Sandeep Surendra Panikar, Na-Keysha Berry, Yi Rao, Abbey Zidel, Jason Stuart Lewis, Patrícia M. R. Pereira · 2023 · Journal of Nuclear Medicine
8. Antibody–Drug Conjugates for the Treatment of Renal Cancer: A Scoping Review on Current Evidence and Clinical Perspectives
   Stefano Sganga, Silvia Riondino, Giovanni Maria Iannantuono, Roberto Rosenfeld, Mario Roselli, Francesco Torino · 2023 · Journal of Personalized Medicine
9. The Future of HER2-Targeted Treatment for Osteosarcoma: Lessons from the Negative Trastuzumab Deruxtecan Results
   Kenji Nakano · 2023 · International Journal of Molecular Sciences
10. Assessing safety concerns of interstitial lung disease associated with antibody-drug conjugates: a real-world pharmacovigilance evaluation of the FDA adverse event reporting system
    Wanlong Lin, Jiabing Xu, Yufang Liao, Xiuxian Lin, Jianhui Yang, Wei Zhuang · 2023 · International Journal of Clinical Pharmacy
11. Targeting HER2 in Biliary Tract Carcinomas: Challenges and Opportunities
    Dieter Koeberle, Ralph Fritsch · 2021 · Oncology Research and Treatment
12. Present Scenario and Future Landscape of Payloads for ADCs: Focus on DNA-Interacting Agents
    Barbara Valsasina, Paolo Orsini, Chiara Terenghi, Alberto Ocaña · 2024 · Pharmaceuticals
13. Nausea and vomiting in an evolving anticancer treatment landscape: long-delayed and emetogenic antibody-drug conjugates
    Yeon Hee Park, Giampaolo Bianchini, Javier Cortés, Luca Licata, Maria Jesus Vidal, Hirotoshi Iihara, Eric J. Roeland, Karin Jordan, Florian Scotté, Lee Steven Schwartzberg et al. · 2025 · Future Oncology
14. Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02
    S.A. Hurvitz, Sherene Loi, Joyce O’Shaughnessy, Alicia F. C. Okines, Sara M. Tolaney, Joohyuk Sohn, Cristina Saura, X. Zhu, David Cameron, Thomas Bachelot et al. · 2025 · Annals of Oncology
15. DNA–drug conjugates enable logic-gated drug delivery amplified by hybridization chain reactions
    Sikai Chen, Miguel López‐Tena, Francesco Russo, Emma E. Watson, Millicent Dockerill, Javier Cabello-García, Sofía Barluenga, Nicolas Winssinger · 2026 · Nature Biotechnology
16. N-terminal selective conjugation method widens the therapeutic window of antibody–drug conjugates by improving tolerability and stability
    Min Ji Ko, Daehae Song, Ju Hee Kim, Jae Yong Kim, Jaehyun Eom, Byungje Sung, Yong-Gyu Son, Young Min Kim, Sang Hoon Lee, Weon‐Kyoo You et al. · 2021 · mAbs
17. Antibody Drug Conjugates in Lung Cancer
    Geoffrey Merle, Alex Friedlaender, Aakash P. Desai, Alfredo Addeo · 2022 · The Cancer Journal
18. Combined inhibition of PARP and ATR synergistically potentiates the antitumor activity of HER2-targeting antibody-drug conjugate in HER2-positive cancers.
    Yongpeng Li, Lin Li, Haoyu Fu, Qing Yao, Lei Wang, Liguang Lou · 2023 · PubMed Central
19. Evaluation of predictive and prognostic value of androgen receptor expression in breast cancer subtypes treated with neoadjuvant chemotherapy
    Zhendong Shi, Yingxue Liu, Shichao Zhang, Shuang-Long Cai, Xu Liu, Jie Meng, Jin Zhang · 2023 · Discover Oncology
20. The efficacy and safety of trastuzumab deruxtecan (T-DXd) in HER2-expressing solid tumours: a single-arm meta-analysis
    Liqiu Kou, Xiu Chen, Xiaolu Xie, Qinglian Wen, Jun Li, Yaling Li · 2023 · Japanese Journal of Clinical Oncology
21. Next-Generation Sequencing in Breast Cancer Patients: Real-World Data for Precision Medicine
    Hyunwoo Lee, Yoon Ah Cho, Deok Geun Kim, Eun Yoon Cho · 2023 · Cancer Research and Treatment
22. Clinical best practices in interdisciplinary management of human epidermal growth factor receptor 2 antibody‐drug conjugates–induced interstitial lung disease/pneumonitis: An expert consensus in China
    Chunwei Xu, Zhanhong Chen, Yuanli Xia, Yanxia Shi, Peifen Fu, Yiding Chen, Xian Wang, Lili Zhang, Hengyu Li, Wenyan Chen et al. · 2024 · Cancer
23. Targeting HER2 in breast cancer with brain metastases: A pharmacological point of view with special focus on the permeability of blood-brain barrier to targeted treatments
    Giorgio Guglielmi, Claudio Zamagni, Marzia Del Re, Romano Danesi, Stefano Fogli · 2024 · European Journal of Pharmacology
24. Cardiac Safety of Reduced Cardiotoxicity Surveillance During HER2-Targeted Therapy
    Anthony Francis Yu, Chau T. Dang, Chaya S. Moskowitz, Akriti Mishra Meza, Patricia Anne DeFusco, Eric J. Oligino, Carol L. Chen, Rachel Ann Sanford, Pamela R. Drullinsky, Jacqueline Bromberg et al. · 2025 · JACC CardioOncology
25. Recent Research Advances in HER2-Positive Breast Cancer Concerning Targeted Therapy Drugs
    J. Li, Xue Li, Ruixin Fu, Yakun Fang, Chunmei Zhang, Bingbing Ma, Yanan Ding, Chuanxin Shi, Qingfeng Zhou · 2025 · Molecules
26. Update Breast Cancer 2020 Part 4 – Advanced Breast Cancer
    Hans Tesch, Volkmar Müller, Achim Wöckel, Johannes Ettl, Erik Belleville, Florian Schütz, Andreas Daniel Hartkopf, Marc Thill, Jens Huober, Peter Andreas Fasching et al. · 2020 · Geburtshilfe und Frauenheilkunde
27. Clinical benefit of treatment after trastuzumab emtansine for HER2-positive metastatic breast cancer: a real-world multi-centre cohort study in Japan (WJOG12519B)
    Takamichi Yokoe, Sasagu Kurozumi, Kazuki Nozawa, Yukinori Ozaki, Tetsuyo Maeda, Shu Yazaki, Mai Onishi, Akihiro Fujimoto, Sayuka Nakayama, Yuko Tsuboguchi et al. · 2021 · Breast Cancer
28. An Anti-HER2 Monoclonal Antibody H 2 Mab-41 Exerts Antitumor Activities in Mouse Xenograft Model Using Dog HER2-Overexpressed Cells
    Nami Tateyama, Teizo Asano, Tomokazu Ohishi, Junko Takei, Hideki Hosono, Ren Nanamiya, Tomohiro Tanaka, Masato Sano, Masaki Saito, Manabu Kawada et al. · 2021 · Monoclonal Antibodies in Immunodiagnosis and Immunotherapy
29. Microgravity: New aspect for breast cancer treatment, a review
    Medha Medha, Amit Roy · 2021 · Acta Astronautica
30. YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development
    Miwa FUJIHARA, Tadahiko Shien, Kazuhiko Shien, Ken Suzawa, Tatsuaki Takeda, Yidan Zhu, Tomoka Mamori, Yusuke Otani, Ryo Yoshioka, Maya Uno et al. · 2021 · International Journal of Molecular Sciences
31. Comparative Study on the Efficacy and Exposure of Molecular Target Agents in Non–small Cell Lung Cancer PDX Models with Driver Genetic Alterations
    Hitomi Jo, Shigehiro Yagishita, Yoshiharu Hayashi, Shoraku Ryu, Mikiko Suzuki, Shinji Kohsaka, Toshihide Ueno, Yuji Matsumoto, Hidehito Horinouchi, Yuichiro Ohe et al. · 2021 · Molecular Cancer Therapeutics
32. ABC6 Consensus: Assessment by a Group of German Experts
    Diana Lüftner, Peter Andreas Fasching, Renate Haidinger, Nadia Harbeck, Christian Jackisch, Volkmar Müller, Eva Schumacher-Wulf, Christoph Thomssen, Michael Untch, Rachel Würstlein · 2022 · Breast Care
33. Intracranial Response Rate in Patients with Breast Cancer Brain Metastases after Systemic Therapy
    Anna Niwińska, Katarzyna Pogoda, Agnieszka Jagiełło-Gruszfeld, Renata Duchnowska · 2022 · Cancers
34. Ribociclib in the Treatment of Hormone-Receptor Positive/HER2-Negative Advanced and Early Breast Cancer: Overview of Clinical Data and Patients Selection
    Maria Chiara Parati, Rebecca Pedersini, Gianluca Perego, Roberto Reduzzi, Tommaso Savio, Mary Cabiddu, Karen Borgonovo, Mara Ghilardi, Andrea Luciani, Fausto Petrelli · 2022 · Breast Cancer Targets and Therapy
35. Systemic Therapy Type and Timing Effects on Radiation Necrosis Risk in HER2+ Breast Cancer Brain Metastases Patients Treated With Stereotactic Radiosurgery
    Christine Park, Evan D. Buckley, Amanda E.D. Van Swearingen, Will Giles, James E. Herndon, John P. Kirkpatrick, Carey K. Anders, Scott Floyd · 2022 · Frontiers in Oncology
36. Current challenges and unmet needs in treating patients with human epidermal growth factor receptor 2-positive advanced breast cancer
    Matti Aapro, Fátima Cardoso, Giuseppe Curigliano, Alexandru E. Eniu, Joseph Gligorov, Nadia Harbeck, Andreas Mueller, Olivia Pagani, Shani Paluch–Shimon, Elżbieta Senkus et al. · 2022 · The Breast
37. CSCO expert consensus on the diagnosis and treatment of breast cancer brain metastasis
    the CSCO expert panel of breast cancer, Tao Wang, Jiayi Chen, Jin Yang, Minjie Fu, Wei Hua, Jia Wang, Yueping Liu, Biyun Wang, Min Yan et al. · 2022 · Translational Breast Cancer Research
38. Neue Therapiemöglichkeiten beim metastasierten HER2-low-Mammakarzinom
    Carsten Denkert, Annette Lebeau, Hans‐Ulrich Schildhaus, Christian Jackisch, Josef Rüschoff · 2022 · Die Pathologie
39. Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases
    Xiaojing Yang, Hanru Ren, Yi Xu, Xue Peng, Wenxi Yu, Zan Shen · 2023 · European journal of medical research
40. Cardiovascular toxicity of tyrosine kinase inhibitors during cancer treatment: Potential involvement of TRPM7
    Qing Liu, Suyao Li, Yuran Qiu, Jiayu Zhang, Francisco J. O. Rios, Zhiguo Zou, Rhian M. Touyz · 2023 · Frontiers in Cardiovascular Medicine
41. Best Foot Forward: Neoadjuvant Systemic Therapy as Standard of Care in Triple-Negative and HER2-Positive Breast Cancer
    Priyanka Sharma, Roisín M. Connolly, Evanthia T. Roussos Torres, Alastair Mark Thompson · 2020 · American Society of Clinical Oncology Educational Book
42. Early, On-Treatment Levels and Dynamic Changes of Genomic Instability in Circulating Tumor DNA Predict Response to Treatment and Outcome in Metastatic Breast Cancer Patients
    Adriana Aguilar‐Mahecha, Josiane Lafleur, Susie Brousse, Olga Savichtcheva, Kimberly A. Holden, Nathan Faulkner, Graham McLennan, Taylor J. Jensen, Mark Basik · 2021 · Cancers
43. The ideal strategies of antibody‒drug conjugate sequential treatment in HER2-expressing metastatic breast cancer: A multi-center real-world study
    Peng, Xuenan, Lan, Bo, Wang, Jiayu, Li, Qiao, Wang, Jiani, Fan, Ying, Luo, Yang, Chen, Shanshan, Mo, Hongnan, Li, Lixi et al. · 2025 · The Breast
44. Trastuzumab deruxtecan in patients with active brain metastases from HER2-positive/low metastatic breast cancer: a retrospective multicenter real-world study
    Fangfang Duan, Xin Hua, Wei Lu, Xingxing Gui, Jingdun Xie, Xudong Wang, Yuyu Ma, Wenyu Zhai, Wen Xia · 2025 · Breast Cancer Research
45. Antibody-drug conjugates in precision oncology
    Barbara Pistilli, Raffaele Colombo, Maria Fernanda Mosele, Sarat Chandarlapaty · 2026 · Cancer Cell
46. Antibody‐drug conjugates targeting CD248 + myofibroblasts effectively alleviate renal fibrosis in mice
    Chao Xu, Shaojie Liu, Fa Yang, Keying Zhang, Yu Li, Xiaolong Zhao, Jiayu Zhang, Tong Lu, Shiqi Lu, Yao Jiang et al. · 2021 · The FASEB Journal
47. Clinicopathologic characteristics and prognostic significance of HER2-low expression in patients with early breast cancer: A systematic review and meta-analysis
    Tong Wei, Dingyuan Wang, Songlin Gao, Xue Lian Wang, Jian Yue, Yi‐Kun Kang, Jie Ju, Zixuan Yang, You Shuai, Peng Yuan · 2023 · Frontiers in Oncology
48. Antibody drug conjugates in older patients: State of the art
    Layal Rached, Arthur Géraud, Maxime Frélaut, Zoé ap Thomas, Vincent Goldschmidt, Geoffroy Béraud-Chaulet, C. Lazarovici, François‐Xavier Danlos, Clémence Henon, Claudia Parisi et al. · 2023 · Critical Reviews in Oncology/Hematology
49. Pharmacokinetics and pharmacodynamics of antibody-drug conjugates for the treatment of patients with breast cancer
    François Cherifi, Angélique Da Silva, Diogo Alexandre Martins-Branco, Ahmad Hussein Awada, Guilherme Nader Marta · 2024 · Expert Opinion on Drug Metabolism & Toxicology
50. Ultrasound combined with microbubble mediated immunotherapy for tumor microenvironment
    Yunfeng Wu, Jiajia Li, Linfeng Shu, Zhaoyu Tian, Siru Wu, Zuohui Wu · 2024 · Frontiers in Pharmacology
51. Efficacy and safety of trastuzumab deruxtecan in treating human epidermal growth factor receptor 2-low/positive advanced breast cancer:A meta-analysis of randomized controlled trials
    Rui Ma, Yixun Shi, Ruijuan Yan, Shiqing Yin, H. Bu, Jie Huang · 2024 · Critical Reviews in Oncology/Hematology
52. Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2024
    Marc Thill, Wolfgang Janni, Ute‐Susann Albert, Maggie Banys‐Paluchowski, Ingo Bauerfeind, Jens‐Uwe Blohmer, Wilfried Budach, Peter Dall, Nina Caroline Ditsch, Eva Maria Fallenberg et al. · 2024 · Breast Care
53. Mechanism and clinical progression of solid tumors bone marrow metastasis
    Ruohan Yang, Lin Jia, Jiuwei Cui · 2024 · Frontiers in Pharmacology
54. Monitoring changing patterns in HER2 addiction by liquid biopsy in advanced breast cancer patients
    Elena Giordani, Matteo Allegretti, Alberto Sinibaldi, Francesco Michelotti, Gianluigi Ferretti, Elena Ricciardi, Giovanna Ziccheddu, Fabio Valenti, Simona Di Martino, Cristiana Ercolani et al. · 2024 · Journal of Experimental & Clinical Cancer Research
55. Novel antibody-drug conjugates based on DXd-ADC technology
    Rong Chen, Zhiwen Ren, Lan Bai, Xuefang Hu, Yuchen Chen, Qiang Ye, Yuan Jia Hu, Jianyou Shi · 2024 · Bioorganic Chemistry
56. Advancements in research and clinical management of interstitial lung injury associated with ADC drugs administration in breast cancer
    Jiayu Zhu, Ruiyuan Jiang, Huanping Zhang, Zi-ru Fang, Huanhuan Zhou, Qing Wei, Xiaojia Wang · 2024 · Discover Oncology
57. Recent advances of antibody-drug conjugates in treating breast cancer with different HER2 status
    Yue Qiu, Y. Eric Shi, Zhujun Chao, Xinyu Zhu, Yan Chen, Linlin Lu · 2025 · Therapeutic Advances in Medical Oncology
58. Real life outcome analysis of breast cancer brain metastases treated with Trastuzumab Deruxtecan
    Alessandra Fabi, Alessandro Rossi, Roberta Caputo, Simona Pisegna, Simone Scagnoli, Francesco Pantano, Giuliana D’Auria, Palma Fedele, Agnese Fabbri, Claudio Vernieri et al. · 2025 · npj Precision Oncology
59. Efficacy and safety of trastuzumab deruxtecan in Chinese patients with HER2-positive and HER2-low advanced breast cancer: a multicenter, observational, real-world study
    Die Sang, Yanfang Su, Yurong Zhang, Yanfeng Guan, Shanmin Fan, Jintao Zhang, Lijun Zheng, Yanling Wang, Ying Guo, Zixuan Lei et al. · 2025 · Therapeutic Advances in Medical Oncology
60. Advancing breast cancer therapy in the era of molecular diagnostics
    Maria Grazia Carnevale, Riccardo Ray Colciago, Maria Carmen De Santis, Laura Cortesi, Cinzia De Marco, Antonio Marra, Andrea Vingiani, Franco Nolè, Giuseppe Curigliano, Giancarlo Pruneri et al. · 2025 · The Breast
61. Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine in Patients With Previously Treated HER2-Positive Metastatic Breast Cancer: A Multicenter, Retrospective Study
    Yizhao Xie, Yi Li, Luo Ting, Die Sang, Peng Yuan, Wěi Li, Huihui Li, Rui Ge, Biyun Wang · 2021 · Frontiers in Oncology
62. No evidence of disease versus residual disease in long-term responders to first-line HER2-targeted therapy for metastatic breast cancer
    Zachary William Neil Veitch, Domen Ribnikar, Derek G. Tilley, Patricia A. Tang, Karen Marie King, Philippe Lucien Bedard, Sasha Lupichuk, David W. Cescon · 2021 · British Journal of Cancer
63. Targeting HER2+ Breast Cancer Brain Metastases: A Review of Brain-Directed HER2-Directed Therapies
    Lauren S. Chiec, Priya Kumthekar · 2022 · CNS Drugs
64. Application of histology-agnostic treatments in metastatic colorectal cancer
    Andrea Sartore Bianchi, Alberto Giuseppe Agostara, Giorgio Patelli, Gianluca Mauri, Elio Gregory Pizzutilo, Salvatore Siena · 2022 · Digestive and Liver Disease
65. Immunological Landscape of HER-2 Positive Breast Cancer
    Santiago Moragón, Cristina Hernándo, Maria Teresa Martinez-Martinez, Marta Tapia, Belén Ortega-Morillo, Ana M. Lluch, Begoña Bermejo, Juan Miguel Cejalvo · 2022 · Cancers
66. Predictive biomarkers for molecularly targeted therapies and immunotherapies in breast cancer
    Mi Jeong Kwon · 2022 · Archives of Pharmacal Research
67. New treatment options for metastatic HER2-low breast cancer
    Carsten Denkert, Annette Lebeau, Hans‐Ulrich Schildhaus, Christian Jackisch, Josef Rüschoff · 2022 · Die Pathologie
68. Outcomes for the first four lines of therapy in patients with HER2-positive advanced breast cancer: results from the SONABRE registry
    Khava I. E. Ibragimova, Sandra M. E. Geurts, Marissa Meegdes, Frans Erdkamp, Joan Barbara Heijns, Jolien Tol, Birgit E. P. J. Vriens, Marcus Wouter Dercksen, Kirsten N. A. Aaldering, Manon J. A. E. Pepels et al. · 2023 · Breast Cancer Research and Treatment
69. Recent Advances in Immunotherapy and Molecular Targeted Therapy for Gastric Cancer
    Yuri Yoshinami, Hirokazu Shoji · 2023 · Future Science OA
70. ‘Targeting’ Improved Outcomes with Antibody-Drug Conjugates in Non-Small Cell Lung Cancer—An Updated Review
    Saurav Verma, Daniel Adam Breadner, Jacques Raphael · 2023 · Current Oncology
71. Modern Management and Diagnostics in HER2+ Breast Cancer with CNS Metastasis
    Surbhi Warrior, Adam Julian Cohen-Nowak, Priya Kumthekar · 2023 · Cancers
72. Current Advancements and Future Perspectives of Immunotherapy in Breast Cancer Treatment
    Maria Vasileiou, Savvas Papageorgiou, Nam Phong Nguyen · 2023 · Immuno
73. The Potential of Trastuzumab Deruxtecan as a Tissue Agnostic Drug
    Jan Trøst Jørgensen · 2023 · Oncology
74. Second line trastuzumab emtansine following horizontal dual blockade in a real-life setting
    Salvatore Del Prete, Liliana Montella, Grazia Arpino, Giuseppe Buono, Carlo Buonerba, Pasquale Dolce, Olga Fiorentino, Maria Aliberti, Antonio Febbraro, Clementina Savastano et al. · 2020 · Oncotarget
75. Mucinous Adenocarcinoma of the Appendix With Histologic Response to Neoadjuvant Chemotherapy: Review of Histologic and Clinical Spectrum of Epithelial Neoplastic Mucinous Lesions of the Appendix
    Mehmet Sitki Copur, Allison M. Cushman‐Vokoun, James C. Padussis, Whitney R. Wedel, Caleb W Schroeder, Daniel Herold, Nicholas J. Lintel, Adam Horn · 2021 · ONCOLOGY
76. SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer
    Rupert Bartsch · 2021 · memo - Magazine of European Medical Oncology
77. Treatment and outcomes of older versus younger women with HER2-positive metastatic breast cancer in the real-world national ESME database
    Mylène Annonay, Lisa Gauquelin, Romain Geiss, Mony Ung, Laurence Cristol-Dalstein, Marie‐Ange Mouret‐Reynier, Anthony Gonçalvès, Sophie Abadie‐Lacourtoisie, Éric François, Christophe Perrin et al. · 2021 · The Breast
78. The first reported case of trastuzumab induced interstitial lung disease associated with anti-neutrophil cytoplasmic antibody vasculitis – A case report and a prospective cohort study on the usefulness of neutrophil derived biomarkers in monitoring vasculitis disease activity during follow-up
    Chen-Han Chang, Chiau‐Jing Jung, Yiming Huang, Lo C, Yih‐Leong Chang, Song‐Chou Hsieh, Ching‐Hung Lin, Yu‐Min Kuo · 2021 · The Breast
79. Design and Synthesis of Novel 7-Ethyl-10-Fluoro-20-O-(Cinnamic Acid Ester)-Camptothecin Derivatives as Potential High Selectivity and Low Toxicity Topoisomerase I Inhibitors for Hepatocellular Carcinoma
    Yin-Peng Bai, Cheng‐Jie Yang, Nan Deng, Mi Zhang, Zhijun Zhang, Lei Li, Yong Chun Zhou, Xiong-Fei Luo, Chuanrui Xu, Bao‐Qi Zhang et al. · 2022 · Biochemical Pharmacology
80. Efficacy and Safety of Neoadjuvant TQB2102 in Locally Advanced or Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: A Randomized, Open-Label, Multicenter, Phase II Trial
    Junjie Li, Wenjuan Zhang, Xiaohua Zeng, Qingyuan Zhang, Li Chen, Jiong Wu, Guang‐Yu Liu, Zhihong Wang, Xiaobo Hu, Yanyan Hu et al. · 2025 · Journal of Clinical Oncology
81. Predictive Biomarkers of Antibody–Drug Conjugate Efficacy for Solid Tumors: Current Challenges and the Potential Role of Quantitative Proteomics
    Nicholas McNamee, Jia Liu, Rebecca C. Poulos, Adel T. Aref, Roger R. Reddel · 2025 · Clinical Cancer Research
82. Molecular and clinical correlates of HER3 expression highlights its potential role as a therapeutic target in melanoma
    Eva R. Shteinman, Ismael A. Vergara, Robert V. Rawson, Serigne Lo, Naoyuki Maeda, Kumiko Koyama, Inês Pires da Silva, Georgina Venetia Long, Richard A. Scolyer, James S. Wilmott et al. · 2023 · Pathology
83. Multidisciplinary management of HER2-positive breast cancer with brain metastases: An evidence-based pragmatic approach moving from pathophysiology to clinical data
    Guido Giordano, Gaia Griguolo, Matteo Landriscina, Icro Meattini, Francesco Carbone, Augusto Leone, Marzia Del Re, Stefano Fogli, Romano Danesi, Antonio Colamaria et al. · 2023 · Critical Reviews in Oncology/Hematology
84. Inetetamab combined with pyrotinib and oral vinorelbine for patients with human epidermal growth factor receptor 2 positive advanced breast cancer: A single-arm phase 2 clinical trial
    Nan Jin, Yi Xu, Siqi Wang, Chunxiao Sun, Xueqi Yan, Fan Yang, Yan Liang, Weiwei Chen, Xiang Huang · 2023 · Cancer Pathogenesis and Therapy
85. Evaluation of targeting αVβ3 in breast cancers using RGD peptide-based agents
    Anders Josefsson, Angel G. Cortez, Jing Yu, Sunipa Majumdar, Abhinav Bhise, Robert F. Hobbs, Jessie R. Nedrow · 2024 · Nuclear Medicine and Biology
86. The therapeutic potential of natural metabolites in targeting endocrine-independent HER-2-negative breast cancer
    Mirosława Püsküllüoğlu, Izabela Michalak · 2024 · Frontiers in Pharmacology
87. Comparison of the Response to Neoadjuvant Therapy Between Immunohistochemistry HER2 (3+) and HER2 (2+)/ISH+ Early-Stage Breast Cancer: A Retrospective Multicenter Cohort Study
    Dechuang Jiao, Guangyu Li, Hao Dai, Jia Wang, Jiao Zhang, Yangyang Hou, Xuhui Guo, Yajie Zhao, Xilong Gong, Zhenzhen Liu · 2024 · The Oncologist
88. Antibody-drug conjugates in solid tumors; new strategy for cancer therapy
    Toshiaki Takakura, Toshio Shimizu, Nobuyuki Yamamoto · 2024 · Japanese Journal of Clinical Oncology
89. Clinical implications of the Drug-Drug Interaction in Cancer Patients treated with innovative oncological treatments
    Fiorenza Santamaria, Michela Roberto, Dorelsa Buccilli, Mattia Alberto Di Civita, Paola Giancontieri, Giulia Maltese, Francesco Nicolella, Andrea Torchia, Simone Scagnoli, Simona Pisegna et al. · 2024 · Critical Reviews in Oncology/Hematology
90. Novel Antibody-Drug-Conjugates in Routine Clinical Practice for the Treatment of Metastatic Breast Cancer: Adherence, Efficacy and Tolerability – Real-World Data from German Breast Centers
    Henning Schäffler, Dorothee Jakob, Sophia T. Huesmann, Kerstin Pfister, Kristina Veselinovic, Fabienne Schochter, Elena Leinert, Visnja Fink, Brigitte Kathrin Rack, Alexander Englisch et al. · 2024 · Geburtshilfe und Frauenheilkunde
91. Antibody-Drug Conjugates in Breast Cancer: The Road Towards Biologically-Informed Selection and Sequencing
    Tess A. O’Meara, Paolo Tarantino, Stefania Morganti, Ilana Miriam Schlam, Ana Christina Garrido-Castro, Sara M. Tolaney · 2025 · Current Oncology Reports
92. Disitamab vedotin in preclinical models of HER2-positive breast and gastric cancers resistant to trastuzumab emtansine and trastuzumab deruxtecan
    Negar Pourjamal, Vadim Le Joncour, György Vereb, Cilla Honkamäki, Jorma J Isola, Jeffrey Victor Leyton, Pirjo Laakkonen, Heikki Joensuu, Márk Barok · 2025 · Translational Oncology
93. Cancer-Related Alopecia Risk and Treatment
    Lily C. Kaufman, Lilia Valentic, Hannah Moulton, Lucy Rose, Brittany Dulmage · 2025 · Current Treatment Options in Oncology
94. Determinants of sensitivity to HER2-targeted antibody drug conjugates in urothelial cancer
    Ziyu Chen, Xinran Tang, Jordan Eichholz, Andrew McPherson, Jasmine Thomas, Karan K. Nagar, Naryan Rustgi, John R. Christin, Fengshen Kuo, Sizhi Paul Gao et al. · 2025 · Nature Communications
95. Advances in EGFR/HER2-directed clinical research on breast cancer
    Louis WC Chow, Erich Ferdiansyah Lie, Masakazu Toi · 2020 · Advances in cancer research
96. Drug-Related Pneumonitis in Cancer Treatment during the COVID-19 Era
    Sara Cherri, Silvia Noventa, Martina Fanelli, Giulio Calandra, Tiziana Prochilo, Claudio Bnà, Giordano Savelli, Alberto Zaniboni · 2021 · Cancers
97. The management of HER2‐positive early breast cancer: Current and future therapies
    Julia Chen, Maree Louise Colosimo, Elgene Lim · 2021 · Asia-Pacific Journal of Clinical Oncology
98. Drug-Induced Interstitial Lung Disease after Anthracycline-Combined Chemotherapy for Breast Cancer: A Case Report and Literature Review
    Hideko Hoshina, Hiroyuki Takei · 2021 · Case Reports in Oncology
99. PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting
    Laura Pizzuti, Eriseld Krasniqi, Isabella Sperduti, Maddalena Barba, Teresa Gamucci, Maria Mauri, Enzo Maria Veltri, Icro Meattini, Rossana Berardi, Francesca Sofia Di Lisa et al. · 2021 · Therapeutic Advances in Medical Oncology
100. Advancing antibody-drug conjugates in gynecological malignancies: myth or reality?
     Marta Nerone, Maria Del Grande, Cristiana Sessa, Ilaria Colombo · 2022 · Exploration of Targeted Anti-tumor Therapy